The Claim
In adults with prior percutaneous coronary intervention but no prior myocardial infarction and LDL cholesterol ≥90 mg/dL, treatment with evolocumab for a median of 4.6 years reduces LDL cholesterol to a median of 41.5 mg/dL compared to a median of 107.0 mg/dL with placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults who had a heart procedure but never had a heart attack and have high LDL cholesterol, taking evolocumab for about 4.6 years lowers LDL cholesterol to 41.5 mg/dL, while those taking a placebo have LDL cholesterol at 107.0 mg/dL.
See the scientific wording
In adults with prior percutaneous coronary intervention but no prior myocardial infarction and LDL cholesterol ≥90 mg/dL, treatment with evolocumab for a median of 4.6 years reduces LDL cholesterol to a median of 41.5 mg/dL compared to 107.0 mg/dL with placebo.
A drug binds to a protein that normally destroys LDL receptors in the liver, allowing more receptors to stay on the liver surface. These receptors then grab LDL cholesterol from the blood and pull it into the liver, where it is broken down. This process rapidly lowers the amount of LDL cholesterol in the bloodstream.
What the research says
1 studyFor people who had a heart stent but never had a heart attack and have very high 'bad' cholesterol, this study found that taking evolocumab for about five years cut their bad cholesterol in half — from 107 to 41.5 — while also lowering their risk of future heart problems.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.